WEKO3
アイテム
{"_buckets": {"deposit": "921125cc-c2fb-4cc2-8238-be7c890b5191"}, "_deposit": {"created_by": 2, "id": "6002", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "6002"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00006002", "sets": ["30"]}, "author_link": ["26220", "26217", "26219", "26221", "26218", "26216"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "22", "bibliographicPageEnd": "9630", "bibliographicPageStart": "9627", "bibliographicVolumeNumber": "15", "bibliographic_titles": [{"bibliographic_title": "Asian Pacific Journal of Cancer Prevention"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin. Accordingly, we investigated the efficacy and safety of aprepitant in patients with head and neck cancer (HNC) receiving combination therapy with cisplatin and 5-FU (FP therapy). Materials and Methods: Twenty patients with HNC were prospectively studied who received a triple antiemetic regimen comprising granisetron (40μg/kg on Days 1-4), dexamethasone (8 mg on Days 1-4), and aprepitant (125 mg on day 1 and 80mg on days 2-5) with FP therapy (cisplatin 20 mg/m2 on days 1-4; 5-FU 400 mg/m2 on days 1-5) (aprepitant group). We also retrospectively studied another 20 HNC patients who received the same regimen except for aprepitant (control group). Results: For efficacy endpoints based on nausea, the aprepitant group showed significantly better results, including a higher rate of complete response (no vomiting and no salvage therapy) for the acute phase (p = 0.0342), although there was no marked difference between the two groups with regard to percentage of patients in whom vomiting was suppressed. There were no clinically relevant adverse reactions to aprepitant. Conclusions: This study suggested that a triple antiemetic regimen containing aprepitant is safe and effective for HNC patients receiving daily cisplatin therapy.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Asian Pacific Journal of Cancer Prevention, 15(22), pp.9627-9630; 2014", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Asian Pacific Organization for Cancer Prevention"}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c National Cancer Center, Korea."}, {"subitem_rights": "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0)."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "15137368", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ishimaru, Kotaro"}], "nameIdentifiers": [{"nameIdentifier": "26216", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takano, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "26217", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsura, Motoyasu"}], "nameIdentifiers": [{"nameIdentifier": "26218", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Nimpei"}], "nameIdentifiers": [{"nameIdentifier": "26219", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kaneko, Kenichi"}], "nameIdentifiers": [{"nameIdentifier": "26220", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Haruo"}], "nameIdentifiers": [{"nameIdentifier": "26221", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "APJCP15_9627.pdf", "filesize": [{"value": "416.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 416800.0, "url": {"label": "APJCP15_9627.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/6002/files/APJCP15_9627.pdf"}, "version_id": "bc8173ee-e0a6-4b3b-8b92-2fd4d2614070"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Antiemetic", "subitem_subject_scheme": "Other"}, {"subitem_subject": "aprepitant", "subitem_subject_scheme": "Other"}, {"subitem_subject": "CINV", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cisplatin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Head and neck cancer", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/35102", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-02-24"}, "publish_date": "2015-02-24", "publish_status": "0", "recid": "6002", "relation": {}, "relation_version_is_last": true, "title": ["Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy"], "weko_shared_id": -1}
Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy
http://hdl.handle.net/10069/35102
http://hdl.handle.net/10069/351024fde68f1-e2b0-4096-b330-e392d8f10feb
名前 / ファイル | ライセンス | アクション |
---|---|---|
APJCP15_9627.pdf (416.8 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-02-24 | |||||
タイトル | ||||||
タイトル | Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Antiemetic | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | aprepitant | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | CINV | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Cisplatin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Head and neck cancer | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ishimaru, Kotaro
× Ishimaru, Kotaro× Takano, Atsushi× Katsura, Motoyasu× Yamaguchi, Nimpei× Kaneko, Kenichi× Takahashi, Haruo |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin. Accordingly, we investigated the efficacy and safety of aprepitant in patients with head and neck cancer (HNC) receiving combination therapy with cisplatin and 5-FU (FP therapy). Materials and Methods: Twenty patients with HNC were prospectively studied who received a triple antiemetic regimen comprising granisetron (40μg/kg on Days 1-4), dexamethasone (8 mg on Days 1-4), and aprepitant (125 mg on day 1 and 80mg on days 2-5) with FP therapy (cisplatin 20 mg/m2 on days 1-4; 5-FU 400 mg/m2 on days 1-5) (aprepitant group). We also retrospectively studied another 20 HNC patients who received the same regimen except for aprepitant (control group). Results: For efficacy endpoints based on nausea, the aprepitant group showed significantly better results, including a higher rate of complete response (no vomiting and no salvage therapy) for the acute phase (p = 0.0342), although there was no marked difference between the two groups with regard to percentage of patients in whom vomiting was suppressed. There were no clinically relevant adverse reactions to aprepitant. Conclusions: This study suggested that a triple antiemetic regimen containing aprepitant is safe and effective for HNC patients receiving daily cisplatin therapy. | |||||
書誌情報 |
Asian Pacific Journal of Cancer Prevention 巻 15, 号 22, p. 9627-9630, 発行日 2014 |
|||||
出版者 | ||||||
出版者 | Asian Pacific Organization for Cancer Prevention | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 15137368 | |||||
権利 | ||||||
権利情報 | c National Cancer Center, Korea. | |||||
権利 | ||||||
権利情報 | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0). | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Asian Pacific Journal of Cancer Prevention, 15(22), pp.9627-9630; 2014 |